{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.0","upperLimit":"197.0","value":"127.0"},{"groupId":"OG001","lowerLimit":"85.0","upperLimit":"142.0","value":"113.0"},{"groupId":"OG002","lowerLimit":"87.0","upperLimit":"143.0","value":"114.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"139"}],"units":"Participants"}],"description":"PFS is defined as time from first dose of study treatment to progression or death due to any cause, based on modified European Society for Bone and Marrow Transplantation (EBMT) criteria per Investigator's assessment","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"Bexarotene Exposed"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG001","title":"Bexarotene Naive"},{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"The analysis was performed in FAS population was defined according to the intention-to-treat principle. This population will include all participants enrolled into the study.","reportingStatus":"POSTED","timeFrame":"Baseline up to Cycle 12, an average of 12 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}